Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical GLYC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Apr 20 | NR7 | Range Contraction | 0.00% |
| Apr 20 | BB Squeeze Ended | Range Expansion | 0.00% |
| Apr 19 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.96% |
| Apr 19 | Bollinger Band Squeeze | Range Contraction | 1.96% |
| Apr 19 | BB Squeeze Started | Range Contraction | 1.96% |
| Apr 19 | BB Squeeze + Upper Band Touch | Range Contraction | 1.96% |
| Apr 19 | Outside Day | Range Expansion | 1.96% |
| Apr 19 | Upper Bollinger Band Touch | Strength | 1.96% |
| Apr 18 | Doji - Bearish? | Reversal | -2.11% |
| Apr 18 | BB Squeeze Ended | Range Expansion | -2.11% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-05-14
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GLYC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 26.05 |
| 52 Week Low | 3.82 |
| Average Volume | 933,957 |
| 200-Day Moving Average | 15.3646 |
| 50-Day Moving Average | 19.4454 |
| 20-Day Moving Average | 16.7825 |
| 10-Day Moving Average | 17.295 |
| Average True Range | 1.0928 |
| ADX | 18.63 |
| +DI | 20.92 |
| -DI | 20.0 |
| Chandelier Exit (Long, 3 ATRs ) | 15.2016 |
| Chandelier Exit (Short, 3 ATRs ) | 18.6984 |
| Upper Bollinger Band | 18.3081 |
| Lower Bollinger Band | 15.2569 |
| Percent B (%b) | 0.78 |
| BandWidth | 18.180843 |
| MACD Line | -0.2988 |
| MACD Signal Line | -0.6122 |
| MACD Histogram | 0.3133 |
| Fundamentals | Value |
|---|---|
| Market Cap | 577.56 Million |
| Num Shares | 32.7 Million |
| EPS | -1.34 |
| Price-to-Earnings (P/E) Ratio | -13.17 |
| Price-to-Sales | 18873.21 |
| Price-to-Book | 3.02 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.48 | ||||
| Resistance 3 (R3) | 18.39 | 18.04 | 18.34 | ||
| Resistance 2 (R2) | 18.04 | 17.83 | 18.08 | 18.29 | |
| Resistance 1 (R1) | 17.84 | 17.70 | 17.94 | 17.93 | 18.25 |
| Pivot Point | 17.49 | 17.49 | 17.54 | 17.53 | 17.49 |
| Support 1 (S1) | 17.29 | 17.28 | 17.39 | 17.38 | 17.05 |
| Support 2 (S2) | 16.94 | 17.15 | 16.98 | 17.01 | |
| Support 3 (S3) | 16.74 | 16.94 | 16.96 | ||
| Support 4 (S4) | 16.83 |
